Astal Laboratories
Close ·
- P/E
- 6.36
Key Fundamentals
MicrocapCommercial ServicesServicesPrice-based figures at the close · TTM
- ROCE
- 9.15%
- Debt to Equity
- 0.15
- EPS (TTM)
- ₹9.20
- Book Value
- ₹77.17
- Market Cap
- —
- P/E (TTM)
- 6.36
- P/B
- 0.76
- ROE
- 7.96%
- Dividend Yield
- 0.00%
- EBITDA
- ₹21.00 Cr
- 52W High
- ₹99.90
- 52W Low
- ₹49.99
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 43
- Weak
- Returns, margins, earnings quality 22% weight
- Valuation
- 68
- Strong
- Cheap vs sector & own history 24% weight
- Growth
- 99
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 57
- Good
- Solvency, leverage, coverage 9% weight
- Momentum
- 14
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 50
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Stock is trading at 0.81 times its book value
Weaknesses
4- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 4.59%
- Company has high debtors of 229 days.
- Promoter holding has decreased over last 3 years: -51.1%
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bearish | 12 | 5 | 2 |
| Oscillators | Neutral | 2 | 5 | 2 |
| Moving Averages | Strong Bearish | 10 | 0 | 0 |
Oscillators
Neutral
Overall
Strong Bearish
Moving Averages
Strong Bearish
Key readings
- RSI (14)
- 38.44
- Neutral
- MACD (12,26,9)
- −3.90
- Bearish
- SMA (50)
- 70.87
- Bearish
- SMA (200)
- 75.58
- Bearish
As of
Growth Rate
From the financial statements below. 1Y: fiscal year to Mar 2026 against Mar 2025.
Revenue
| 1Y | +290.63% |
|---|
Net profit
| 1Y | +66.67% |
|---|
Operating cash flow
| 1Y | Outflow widened by ₹5 Cr |
|---|
Operating margin· change in pp
| 1Y | −11.91 pp |
|---|
Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.
Revenue by year
| Mar 2025 | ₹64.00 Cr |
|---|---|
| Mar 2026 | ₹250 Cr |
Net profit by year
| Mar 2025 | ₹9.00 Cr |
|---|---|
| Mar 2026 | ₹15.00 Cr |
Quarterly Results
₹ Cr| Particulars | Mar 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Sales | 23.47 | 52.24 | 134 | 101 |
| Expenses | 19.29 | 48.69 | 124 | 88.69 |
| Operating Profit | 4.18 | 3.55 | 10.19 | 12.25 |
| OPM % | 17.81% | 6.8% | 7.6% | 12.14% |
| Other Income | 0.04 | 0.04 | 0.1 | 0.14 |
| Interest | 0.27 | 0.33 | 1.09 | 1.18 |
| Depreciation | 0.1 | 0.12 | 0.86 | 0.86 |
| PBT | 3.85 | 3.14 | 8.34 | 10.35 |
| Tax % | 28.57% | 24.52% | 7.91% | 8.99% |
| Net Profit | 2.74 | 2.36 | 7.68 | 9.42 |
| EPS (₹) | 2.79 | 2.19 | 1.82 | 2.15 |
Profit & Loss
₹ Cr| Particulars | Mar 2025 | Mar 2026 |
|---|---|---|
| Sales | 64 | 250 |
| Expenses | 51 | 229 |
| Operating Profit | 13 | 21 |
| OPM % | 20% | 8% |
| Other Income | 0 | 0 |
| Interest | 1 | 2 |
| Depreciation | 0 | 1 |
| PBT | 12 | 18 |
| Tax % | 25% | 17% |
| Net Profit | 9 | 15 |
| EPS (₹) | 9.08 | 3.48 |
| Div. Payout % | 0% | 0% |
Balance Sheet
₹ Cr| Particulars | Mar 2025 | Mar 2026 |
|---|---|---|
| Equity Capital | 10 | 42 |
| Reserves | 26 | 292 |
| Borrowings | 13 | 49 |
| Other Liabilities | 14 | 136 |
| Total Liabilities | 63 | 519 |
| Fixed Assets | 11 | 64 |
| CWIP | 0 | 0 |
| Investments | 0 | 203 |
| Other Assets | 52 | 251 |
| Total Assets | 63 | 519 |
Cash Flow
₹ Cr| Particulars | Mar 2025 | Mar 2026 |
|---|---|---|
| Operating | −13 | −18 |
| Investing | −8 | −2 |
| Financing | 3 | 3 |
| Net Cash Flow | −17 | −17 |
| Free Cash Flow | −18 | −19 |
| CFO/EBITDA | −96 | −80 |
Ratios
| Particulars | Mar 2025 | Mar 2026 |
|---|---|---|
| Debtor Days | 157 | 229 |
| Inventory Days | 112 | 112 |
| Days Payable | 82 | 206 |
| Cash Conversion Cycle | 187 | 135 |
| Working Capital Days | 97 | 113 |
| ROCE % | — | 9% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Astal Laboratories insights
60 extracted metrics across FY10–FY27.
Documents
- 14 Aug 2026
- 30 May 2026
- 30 May 2026
- 14 Feb 2026
- 14 Nov 2025
- General announcements 14 Oct 2026
- General announcements 30 Sep 2026
Frequently Asked Questions about Astal Laboratories
What does Astal Laboratories Ltd do?
Where is Astal Laboratories Ltd (ASTALLTD) listed?
Which sector does Astal Laboratories Ltd belong to?
What is the PE ratio of Astal Laboratories Ltd?
What is the 52-week high and low of Astal Laboratories Ltd?
What is the Return on Equity (ROE) of Astal Laboratories Ltd?
Company Information
Astal Laboratories Ltd is engaged in Manufacturing and Trading of all kinds of active Pharmaceutical Ingredients (Bulk Drugs).
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/512600.md for Astal Laboratories Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.